Of these studies, 8 studies assessed the association between CDH13 methylation and bladder cancer risk, 5 studies evaluated the relationship between CDH13 methylation and gender, 5 studies explored the association between CDH13 methylation and tumor number, 4 studies reported the tumor grade (grade 3 vs grade 1-2), and 5 studies evaluated the effect of clinical stage (T2-T4 vs Ta-T1). Here, CDH13 is linked to urinary bladder cancer.